Lenalidomide Eugia (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4‑E3 ubiquitin ligase complex, causing degradation of the transcription factors Ikaros and Aiolos. This leads to immunomodulation, anti‑angiogenic effects, and programmed cell death of malignant plasma cells, while also enhancing natural‑killer cell activity.

The specific dose of Lenalidomide Eugia is determined by the prescribing clinician based on the patient’s diagnosis, disease stage, renal function, and other individual factors. Healthcare professionals tailor the regimen to achieve optimal therapeutic benefit while managing safety.

Lenalidomide is classified as having unknown pregnancy and lactation categories, but it is known to be teratogenic. It should not be used during pregnancy, and effective contraception is required for both male and female patients of reproductive potential. Breastfeeding is generally discouraged while on therapy.

To order Lenalidomide Eugia, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lenalidomide belongs to the immunomodulatory imide drug (IMiD) class, similar to thalidomide and pomalidomide. Compared with thalidomide, lenalidomide generally shows higher potency, a more favorable side‑effect profile regarding neuropathy, and stronger anti‑angiogenic activity, though all share teratogenic risk and require careful monitoring.

Lenalidomide Eugia should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct light. Keep the product out of reach of children and avoid exposing it to excessive heat or humidity to maintain stability.

Lenalidomide Eugia is administered orally, usually as a tablet taken with or without food as directed by the prescriber. Patients should follow the dosing schedule provided by their healthcare professional and report any missed doses or side‑effects promptly.

Serious risks associated with Lenalidomide include venous thromboembolism, severe neutropenia that can lead to infections, secondary primary malignancies, and rare severe skin reactions such as Stevens‑Johnson syndrome. Regular monitoring of blood counts and vigilance for signs of clotting or infection are essential.

Lenalidomide should not be used by patients who are pregnant, those who cannot use effective contraception, or individuals with known hypersensitivity to lenalidomide or any component of the formulation. Caution is also advised for patients with severe renal impairment or a history of thromboembolic events.